In a little-noticed move, the Biden administration has hit the pause button on a rule that would prevent the federal government from using a controversial legal provision for combating the high prices of products developed with taxpayer dollars.
The move amounts to an about-face after the White House left the rule, which was proposed earlier this year by the Trump administration, on its regulatory agenda last month. However, the latest decision suggests the Biden administration is responding to pressure to widen access to medicines and vaccines, especially those funded in part by the U.S. treasury, in the face of the Covid-19 pandemic.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
